Prescient Therapeutics (ASX:PTX) Total Stockholders Equity : A$15.65 Mil (As of Dec. 2024)

View and export this data going back to 1986. Start your Free Trial

What is Prescient Therapeutics Total Stockholders Equity?

Prescient Therapeutics's Total Stockholders Equity for the quarter that ended in Dec. 2024 was A$15.65 Mil. It refers to the net assets owned by shareholders. It does not include minority interest.

Total Stockholders Equity is used to calculate Book Value per Share. Prescient Therapeutics's Book Value per Share for the quarter that ended in Dec. 2024 was A$0.02. The ratio of a company's debt over equity can be used to measure how leveraged this company is. Prescient Therapeutics's Debt-to-Equity for the quarter that ended in Dec. 2024 was 0.00.

Prescient Therapeutics Total Stockholders Equity Historical Data

The historical data trend for Prescient Therapeutics's Total Stockholders Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Prescient Therapeutics Total Stockholders Equity Chart

Prescient Therapeutics Annual Data

Trend

Jun15

Jun16

Jun17

Jun18

Jun19

Jun20

Jun21

Jun22

Jun23

Jun24

Total Stockholders Equity

Get a 7-Day Free Trial

11.19

20.43

16.76

26.08

18.07

Prescient Therapeutics Semi-Annual Data
	Jun15	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23	Jun24	Dec24
Total Stockholders Equity	Get a 7-Day Free Trial															24.80	26.08	22.61	18.07	15.65

Prescient Therapeutics (ASX:PTX) Total Stockholders Equity Explanation

1. Total Stockholders Equity is used to calculate Book Value per Share.

Prescient Therapeutics's Book Value per Share for the quarter that ended in Dec. 2024 is

Book Value per Share	=	(Total Stockholders Equity	-	Preferred Stock)	/	Shares Outstanding (EOP)
	=	(15.645	-	0)	/	805.320
	=	0.02

2. The ratio of a company's debt over equity can be used to measure how leveraged this company is.

Prescient Therapeutics's Debt-to-Equity for the quarter that ended in Dec. 2024 is

Debt-to-Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(0.034	+	0)	/	15.645
	=	0.00

Prescient Therapeutics Total Stockholders Equity Related Terms

Thank you for viewing the detailed overview of Prescient Therapeutics's Total Stockholders Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

Prescient Therapeutics Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Prescient Therapeutics Ltd (ASX:PTX) » Definitions » Total Stockholders Equity

Comparable Companies

Traded in Other Exchanges

N/A

Address

Level 4, 100 Albert Road, South Melbourne, Melbourne, VIC, AUS, 3205

Website

https://www.ptxtherapeutics.com

Prescient Therapeutics Ltd is a clinical-stage oncology company. The company develops novel compounds for the treatment of a range of cancers in Australia. Its product in the pipeline includes OmniCAR; PTX-100 and PTX-200. OmniCAR is a universal immune receptor platform enabling controllable T-cell activity and multi-antigen targeting with a single cell product.

Prescient Therapeutics Headlines

No Headlines